Lymphoma & Myeloma 2014: An International Congress on Hematologic Malignancies

Since its inception in 2000, this Congress has grown to nearly 1,000 attendees from over 40 countries, becoming the premier forum on the latest advances in lymphoma, myeloma and related disorders. This dynamic three-day educational event will include numerous opportunities for lively interaction via audience polling on challenging clinical scenarios, expert-guided discussions, and exciting debates on current clinical controversies. Attendees from all relevant medical specialties will be able to benefit from case-based discussions and didactic lectures incorporating aspects of molecular biology, pathology, immunology and translational and clinical research. Attendees can expect to leave this conference with not only a greater understanding of how to use novel agents safely and with improved patient outcomes but also a thorough understanding of how hypothesis-driven translational and clinical research has lead to the development of these promising agents and novel therapeutic combinations.